Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-02
DOI
10.1007/s13318-018-0526-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
- (2018) Tian Zhou et al. BIOMATERIALS
- Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
- (2018) Tristan D. McPherson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat
- (2017) Beat M. Jucker et al. JOURNAL OF CONTROLLED RELEASE
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
- (2016) Andrew Owen et al. ADVANCED DRUG DELIVERY REVIEWS
- Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
- (2016) Anthony T. Podany et al. CLINICAL PHARMACOKINETICS
- The promise and pitfalls of long-acting injectable agents for HIV prevention
- (2016) Raphael J. Landovitz et al. Current Opinion in HIV and AIDS
- Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection
- (2015) Tae Eun Park et al. Expert Review of Anti-Infective Therapy
- Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
- (2015) Kerri J. Penrose et al. JOURNAL OF INFECTIOUS DISEASES
- The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge
- (2015) J. Radzio et al. Science Translational Medicine
- A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
- (2015) Chasity D. Andrews et al. Science Translational Medicine
- Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam
- (2015) Melinda J. Reese et al. XENOBIOTICA
- Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
- (2015) Gary David Bowers et al. XENOBIOTICA
- Cabotegravir long-acting for HIV-1 prevention
- (2015) Chasity D. Andrews et al. Current Opinion in HIV and AIDS
- Formulation and pharmacology of long-acting cabotegravir
- (2015) Christine Trezza et al. Current Opinion in HIV and AIDS
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
- (2014) Tomokazu Yoshinaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
- (2014) C. D. Andrews et al. SCIENCE
- Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008
- (2013) Nikolas Wada et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
- (2013) Susan L. Ford et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
- (2013) W. Spreen et al. HIV CLINICAL TRIALS
- Long-acting injectable antiretrovirals for HIV treatment and prevention
- (2013) William R. Spreen et al. Current Opinion in HIV and AIDS
- Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744
- (2012) Susan L. Ford et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started